In a pharmaceutical landscape undergoing profound transformation, Medical Affairs and patient-centricity is no longer a simple slogan.
It has become a strategic cornerstone for improving the real-world impact of therapeutic innovations and responding to the growing expectations of patients and healthcare stakeholders.
This article explores the most recent conceptual and operational advances in this shift — from patient-centricity approaches to patient-partner models — drawing on insights from recent scientific and strategic publications.
Source:
https://pubmed.ncbi.nlm.nih.gov/41297848/
Medical Affairs and patient-centricity: a strategy centred on the patient
The role of Medical Affairs has evolved significantly over the past decades.
Historically focused on scientific support for commercial teams and R&D, Medical Affairs is now increasingly positioned as a key driver of patient-centricity.
This transformation responds to two major challenges.
First, patients’ expectations have expanded far beyond therapeutic efficacy alone.
Patients increasingly expect their real needs, lived experiences and constraints to be understood and integrated into clinical and medical decision-making processes.
Source:
https://www.sciencedirect.com/science/article/pii/S1359644623001204
Second, Medical Affairs faces a growing need to demonstrate the value generated by its activities, beyond scientific publications, toward a measurable impact on care pathways, outcomes and decision-making.
In this context, patient-centricity becomes not only an ethical ambition, but also a strategic requirement for the Medical Affairs function.
“Patient-centricity” versus “patient-partner”: a major conceptual shift
A recent review article published in Drug Discovery Today by Sébastien Reig and Christel Becker highlights a fundamental evolution:
Medical Affairs must move beyond traditional patient-centricity, where the focus is primarily on understanding patient needs, toward a patient-partner model.
In this model, the patient is no longer viewed solely as a recipient of care, but as an active contributor to value creation and care optimisation.
According to the authors, this shared approach enables better alignment between medical priorities and patients’ lived realities, positioning patients as informed participants in decisions that directly affect them.
Source:
https://pubmed.ncbi.nlm.nih.gov/41297848/
This evolution marks a shift from listening to patients to working with patients, fundamentally redefining the scope of patient-centricity.
Conceptual frameworks supporting the evolution of Medical Affairs
Several recent publications propose structured frameworks to support this transformation.
A five-pillar framework to strengthen patient-centricity
Dahlia Amin and Pol Vandenbroucke propose a framework structured around five interconnected domains:
medical strategy, communication, evidence generation, patient engagement, and care experience.
Their work also highlights emerging dimensions such as digital health and therapeutic education as critical enablers of patient-centricity within Medical Affairs.
Source:
https://www.sciencedirect.com/science/article/pii/S1359644623001204
Strategic integration of the patient-partner
Other analyses, including those proposed by ZS Associates, offer maturity models enabling pharmaceutical companies to assess how effectively patients are integrated into decision-making processes.
These models help organisations identify gaps between declared patient-centric ambitions and actual operational practices.
Source:
https://www.zs.com/insights/patient-centricity-framework-for-medical-affairs-pharma
A long-term vision for Medical Affairs
The McKinsey report previously cited outlines a vision for Medical Affairs by 2030, showing how the function can expand its impact by:
- leveraging data and analytics,
- transforming therapeutic engagement models,
- integrating artificial intelligence,
- and strengthening evidence generation focused on patient outcomes.
In this vision, patient-centricity becomes a core performance driver, rather than a peripheral initiative.
Why this shift is decisive for the pharmaceutical industry
The growing focus on patient-centricity is not driven solely by ethical considerations.
It also responds to clear economic and organisational needs.
First, improved adoption of therapeutic innovations.
Active patient engagement supports treatment acceptance, adherence and persistence, directly influencing real-world effectiveness.
Second, generation of tangible evidence beyond clinical trials.
Patient experience data increasingly inform payers, regulators and HTA bodies, complementing traditional clinical endpoints.
Third, strengthening trust between patients, healthcare professionals and the pharmaceutical industry.
Moving beyond transactional interactions toward sustained, value-based relationships is now essential for long-term credibility.
Challenges and future perspectives
Despite conceptual progress, significant challenges remain.
Measuring the real impact of patient-centric initiatives is still complex and requires robust, standardised indicators that go beyond qualitative feedback.
Authentically integrating patient voices — rather than limiting engagement to consultation — demands deep organisational transformation, while navigating strict regulatory constraints.
Finally, combining patient insights, real-world data and clinical evidence represents a major opportunity for Medical Affairs to demonstrate its strategic contribution, but also implies a genuine paradigm shift in how evidence is generated and valued.
Conclusion
The patient-centricity evolution of Medical Affairs is far more than a conceptual trend.
It represents a strategic lever for the pharmaceutical industry in the 21st century.
By moving from a posture focused on understanding patient needs to one based on true collaboration with patients, Medical Affairs can play a central role in creating clinical, economic and societal value.
Through structured frameworks, integration of the patient-partner model, and mobilisation of measurable evidence, the Medical Affairs function positions itself as a catalyst for responsible innovation, serving both patients and the broader healthcare ecosystem.
